• Dyne Therapeutics granted inducement equity awards to 14 new hires under its 2024 Inducement Stock Incentive Plan.
• Non-statutory stock options cover 278,100 shares, priced at the Sept. 15 Nasdaq closing price, with a 10-year term.
• Options vest over four years, starting with 25% after one year, then quarterly installments, subject to continued service.
• Restricted stock units cover 88,400 shares, vesting in four equal annual installments over four years, subject to continued service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609171605PRIMZONEFULLFEED9829203) on September 17, 2026, and is solely responsible for the information contained therein.